{"id":"peginterferon-alfa-2b-peg2b","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"20-40%","effect":"Myalgia"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PEG2b achieves this by binding to the interferon-alpha receptor, triggering a cascade of signaling events that ultimately lead to the production of antiviral proteins and the activation of immune cells. This results in the inhibition of viral replication and the enhancement of the body's natural defenses against viral infections.","oneSentence":"Peginterferon alfa-2b (PEG2b) is a pegylated form of interferon alfa-2b, which works by stimulating the body's immune system to fight viral infections.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:05.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00302081","phase":"PHASE3","title":"Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08","conditions":"Hepatitis C, Chronic","enrollment":696},{"nctId":"NCT00104052","phase":"PHASE3","title":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT01641666","phase":"PHASE3","title":"Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01054742","phase":"","title":"Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Hepatitis C","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 054031"],"phase":"phase_3","status":"active","brandName":"Peginterferon alfa-2b (PEG2b)","genericName":"Peginterferon alfa-2b (PEG2b)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alfa-2b (PEG2b) is a pegylated form of interferon alfa-2b, which works by stimulating the body's immune system to fight viral infections. Used for Chronic hepatitis C, Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}